Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings BeOne Medicines AG: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: BeOne Medicines AG
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses: BeOne Medicines AG
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.46 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.

Rating Financials

BeOne Medicines AG SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

BeOne Medicines AG SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

BeOne Medicines AG SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

BeOne Medicines AG SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

BeOne Medicines AG SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.94TCr -
4.3TCr
AAA
3.27TCr -
B
- -
3.03TCr
AAA
2.51TCr
A
1.35TCr - - - - -
1.33TCr
BBB
1.3TCr
AA
1.21TCr -
A
- -
1.12TCr
AAA
Average 2.24TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ONC Stock
  4. Ratings BeOne Medicines AG
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!